Please Wait...

In The News

A wide variety of online and print media sources throughout the world have covered Bioclinica.

In The News

November 6, 2017

In a Company statement picked up by the Journal of Clinical Studies, Bioclinica President and CEO John Hubbard says, “Combining the MDDX technology suite with Bioclinica, including advanced cloud research image management and services, is a perfect match, especially for sponsors who want the assurance that the critical medical imaging component of a clinical trial is managed efficiently, accurately, and reliably, regardless of where the trial is held in the world.“

Applied Clinical Trials covers the news of Bioclinica’s acquisition of Silicon Valley-based MDDX Research & Informatics. With the acquisition, Bioclinica adds advanced cloud research image management and submission technologies to our extensive suite of medical imaging and eHealth solutions. As the backbone of Bioclinica's SMART solution, the technology is a major leap forward in the image submission process for clinical research sites.

Contract Pharma reports Breaking News of Bioclinica’s acquisition of MDDX, a Silicon-Valley based technology disruptor in life sciences.

As reported in Clinical Informatics News, the MDDX platform is FDA 21 CFR Part 11 compliant. Powered by artificial intelligence and machine-learning technologies, the technology integrates more than 1,500 screening and de-identification rules to detect image issues and automatically de-identify any standard image type. An online hosting environment offers real-time access to imaging data along with audit trail transparency.

In this Outsourcing Pharma article, MDDX founder Dan Gebow and Bioclinica President Medical Imaging & eHealth Solutions David Herron tell Melissa Fassbender about the acquisition and how it gives sponsors and CROs access to medical imaging technology, which can help determine patient clinical trial eligibility in under an hour.

More on the MDDX acquisition and what it brings to clinical research sites and the life sciences industry in Fierce Biotech.

August 4, 2017

July 20, 2017

May 9, 2017

May 1, 2017

April 3, 2017

February 22, 2017

January 31, 2017

October 3, 2016

August 12, 2016

August 9, 2016

August 1, 2016

July 26, 2016

July 25, 2016

June 27, 2016

May 26, 2016

April 20, 2016

April 19, 2016

April 4, 2016

April 1, 2016



Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

What's next from Bioclinica? Hear if first during #PCTrials Europe next week in Amsterdam!
bioclinica (5 hours ago)
Join Bioclinica's Justin Hunt on Nov. 28 in a live webinar! Find out how to overcome common hurdles in CTMS impleme…
bioclinica (Yesterday)
Another CRO seeing big gains in the sites payments process! Access the Case Study here
bioclinica (Yesterday)
Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials.
bioclinica (Yesterday)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will give a…
bioclinica (Yesterday)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will giv…
bioclinica (Yesterday)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices